Scientists have shown that treating COVID-19 patients with severe respiratory complications with an IL-6 signalling inhibitor improved their symptoms.
List view / Grid view
Filter the results
A preliminary analysis of data from the first COVID-19 pneumonia patients enrolled in the ODYSSEY trial revealed that tradipitant may expedite clinical improvement.
The portfolio will be offered to low- and lower-middle-income countries to help financially strained healthcare systems care for COVID-19 patients.
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone.